Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.61 |
| ▸ | PKLR | P30613 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514071 | 0.94 | PKM (0.56) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL1020435 | 0.92 | FFAR4 (0.54) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL560493 | 0.88 | CA12 (0.54) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL29437166 | 0.88 | CA12 (0.54) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL3726506 | 0.85 | PKM (0.45) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL2878663 | 0.85 | PKM (0.45) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL31248492 | 0.85 | PKM (0.45) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL2224714 | 0.83 | PKM (0.65) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL4611622 | 0.80 | PKM (0.41) | PKMPKLRNPC1RAB9AMAPT | |
| SCHEMBL2986914 | 0.80 | PKM (0.66) | PKMPKLRNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| EP-0583960-B1 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | LILLY CO ELI (US) | 1997-05-21 | — | — | EP | claimed |
| US-5387681-A | Reacting a bicyclic aromatic compound with a complex of sulfur trioxide-N,N-dimethylformamide; water miscible, non-reactive solvent; thionyl halide | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | claimed |
| EP-0583960-A2 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | ELI LILLY AND COMPANY (US) | 1994-02-23 | — | — | EP | claimed |
| EP-0254577-B1 | SYNTHESIS OF BICYCLIC AROMATIC SULFONYL CHLORIDES | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | claimed |
| EP-0254577-A1 | Synthesis of bicyclic aromatic sulfonyl chlorides | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | claimed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4596534-A1 | NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION | University of Copenhagen (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2025075722-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115687-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORP USA (US) | 2025-04-10 | — | — | US | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996025934-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1995028397-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| US-5387681-A | Reacting a bicyclic aromatic compound with a complex of sulfur trioxide-N,N-dimethylformamide; water miscible, non-reactive solvent; thionyl halide | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0583960-A2 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | ELI LILLY AND COMPANY (US) | 1994-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | PKM 266/4885PKLR 177/4885NPC1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.